In the growing field of personalized medicine, scientists at Yale University have found promising evidence that a simple ...

Molecular residual disease detection may help identify patients with EGFR-mutated NSCLC who could benefit from prolonged ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by ...

Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall ...

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced non–small cell lung cancer.